Head and neck squamous cell carcinoma in adults aged 45 or younger-an analysis of two tertiary cancer centres.

IF 2.5 3区医学 Q3 ONCOLOGY

Strahlentherapie und Onkologie Pub Date : 2025-10-01 Epub Date: 2025-08-21 DOI:10.1007/s00066-025-02448-2

Charlotte Frei, Soeren Schnellhardt, Sabine Semrau, Sarina K Mueller, Manuel Weber, Justus Kaufmann, Rainer Fietkau, Sophia Drabke, Marlen Haderlein

{"title":"Head and neck squamous cell carcinoma in adults aged 45 or younger-an analysis of two tertiary cancer centres.","authors":"Charlotte Frei, Soeren Schnellhardt, Sabine Semrau, Sarina K Mueller, Manuel Weber, Justus Kaufmann, Rainer Fietkau, Sophia Drabke, Marlen Haderlein","doi":"10.1007/s00066-025-02448-2","DOIUrl":null,"url":null,"abstract":"Purpose: The aim of this study was to evaluate the outcome, especially disease-free survival (DFS) and recurrence patterns, in patients with a maximum age of 45 years at first diagnosis of head and neck squamous cell carcinoma (HNSCC).Methods: We retrospectively reviewed data from 79 patients with newly diagnosed HNSCC aged 45 or younger without distant metastasis who underwent postoperative or definitive radio(chemo)therapy in either the Department of Radiation Oncology at the University Hospital of Erlangen or the Department of Radiation Oncology at the University Hospital of Mainz between September 2006 and December 2023. The Kaplan-Meier method was used to calculate survival and recurrence rates. In univariate analysis, the log-rank test was used to correlate patient-/tumour- and treatment-related parameters to survival and recurrence rates.Results: The overall survival rate was 79.7% at 2 years and 67.1% at 5 years. The DFS rate was 73.4% at 2 years and 67.1% at 5 years. Cumulatively, 14.6% of patients in the postoperative arm had locoregional recurrences at 2 years and 23.0% at 5 years, while 25.7% of patients in the definitive arm had local recurrences at 2 years and 33.1% at 5 years (p = 0.36). The rate of distant metastasis was 19.2% in the postoperative arm at 2 years and 21.6% at 5 years. In the definitive arm, the distant metastasis rate was 20.7% at 2 years and 28.6% at 5 years (p = 0.49). Disease-free survival was significantly improved in patients who drank little or no alcohol (p = 0.005) and in patients with a low UICC stage (p < 0.001). No differences in DFS were observed for different primary tumour locations or treatment modalities.Conclusion: Locoregional recurrences were the most common site of recurrence, regardless of tumour location and treatment modality. Therefore, future study designs in this patient cohort should potentially investigate intensified treatment approaches.","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1049-1057"},"PeriodicalIF":2.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12488828/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Strahlentherapie und Onkologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00066-025-02448-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The aim of this study was to evaluate the outcome, especially disease-free survival (DFS) and recurrence patterns, in patients with a maximum age of 45 years at first diagnosis of head and neck squamous cell carcinoma (HNSCC).

Methods: We retrospectively reviewed data from 79 patients with newly diagnosed HNSCC aged 45 or younger without distant metastasis who underwent postoperative or definitive radio(chemo)therapy in either the Department of Radiation Oncology at the University Hospital of Erlangen or the Department of Radiation Oncology at the University Hospital of Mainz between September 2006 and December 2023. The Kaplan-Meier method was used to calculate survival and recurrence rates. In univariate analysis, the log-rank test was used to correlate patient-/tumour- and treatment-related parameters to survival and recurrence rates.

Results: The overall survival rate was 79.7% at 2 years and 67.1% at 5 years. The DFS rate was 73.4% at 2 years and 67.1% at 5 years. Cumulatively, 14.6% of patients in the postoperative arm had locoregional recurrences at 2 years and 23.0% at 5 years, while 25.7% of patients in the definitive arm had local recurrences at 2 years and 33.1% at 5 years (p = 0.36). The rate of distant metastasis was 19.2% in the postoperative arm at 2 years and 21.6% at 5 years. In the definitive arm, the distant metastasis rate was 20.7% at 2 years and 28.6% at 5 years (p = 0.49). Disease-free survival was significantly improved in patients who drank little or no alcohol (p = 0.005) and in patients with a low UICC stage (p < 0.001). No differences in DFS were observed for different primary tumour locations or treatment modalities.

Conclusion: Locoregional recurrences were the most common site of recurrence, regardless of tumour location and treatment modality. Therefore, future study designs in this patient cohort should potentially investigate intensified treatment approaches.

Abstract Image

查看原文本刊更多论文

45岁或以下成人头颈部鳞状细胞癌——两个三级癌症中心的分析

目的：本研究的目的是评估头颈部鳞状细胞癌（HNSCC）首次诊断时最大年龄为45岁的患者的预后，特别是无病生存（DFS）和复发模式。方法：我们回顾性回顾了79例新诊断的45岁或45岁以下无远处转移的HNSCC患者的资料，这些患者在2006年9月至2023年12月期间在埃尔兰根大学医院放射肿瘤科或美因茨大学医院放射肿瘤科接受了术后或最终放化疗。Kaplan-Meier法计算生存率和复发率。在单变量分析中，对数秩检验用于将患者/肿瘤和治疗相关参数与生存率和复发率联系起来。结果：2年生存率为79.7%，5年生存率为67.1%。2年DFS为73.4%，5年DFS为67.1%。总的来说，术后组14.6%的患者在2年和5年有局部复发，23.0%的患者在5年有局部复发，而最终组25.7%的患者在2年和5年有局部复发（p = 0.36）。术后2年时远处转移率为19.2%，5年时为21.6%。确诊组2年远处转移率为20.7%，5年远处转移率为28.6% （p = 0.49）。少饮酒或不饮酒的患者（p = 0.005）和低UICC分期的患者（p ）的无病生存率显著提高。结论：无论肿瘤位置和治疗方式如何，局部区域复发是最常见的复发部位。因此，在该患者队列中，未来的研究设计应该潜在地研究强化治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Strahlentherapie und Onkologie 医学-核医学

CiteScore

5.70

自引率

12.90%

发文量

141

审稿时长

3-8 weeks

期刊介绍： Strahlentherapie und Onkologie, published monthly, is a scientific journal that covers all aspects of oncology with focus on radiooncology, radiation biology and radiation physics. The articles are not only of interest to radiooncologists but to all physicians interested in oncology, to radiation biologists and radiation physicists. The journal publishes original articles, review articles and case studies that are peer-reviewed. It includes scientific short communications as well as a literature review with annotated articles that inform the reader on new developments in the various disciplines concerned and hence allow for a sound overview on the latest results in radiooncology research. Founded in 1912, Strahlentherapie und Onkologie is the oldest oncological journal in the world. Today, contributions are published in English and German. All articles have English summaries and legends. The journal is the official publication of several scientific radiooncological societies and publishes the relevant communications of these societies.